Bio-Rad Laboratories, Inc. Class A Common Stock vs Synchrony Financial — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Synchrony Financial trades at $78.37 (market cap $25.44B). The key difference: Synchrony Financial is far larger — about 2.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Synchrony Financial pays a 1.74% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SYF | |
|---|---|---|
Market Cap | $9.39B | $25.44B |
Sector | Health | Financials |
52-Week High | $356.25 | $88.47 |
52-Week Low | $241.71 | $63.78 |
Enterprise Value | $9.14B | — |
Dividend Yield | — | 1.74% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Synchrony Financial (SYF) trades at $78.59, down 0.1% on the day, with a bullish technical outlook supported by moving averages and strong institutional backing. The stock shows robust fundamentals with a P/E of 8.02, net income margin of 23.4%, and consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.59 versus $2.14 expected. Recent news highlights partnerships like CareCredit's integration with Stripe, enhancing growth prospects.
SYF presents a compelling buy opportunity with a consensus price target of $86.33, offering ~10% upside, driven by aggressive buybacks, stable credit trends, and positive analyst sentiment (62.5% buy ratings). Risks include potential consumer spending slowdowns and competitive pressures in the financial services sector, but strong cash flow and dividend payments support shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →